[{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Global Antibiotics Research and Development Partnership","sponsor":"Parexel | KCAS Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Zoliflodacin","moa":"DNA gyrase | Topoisomerase IV","graph1":"Undisclosed","graph2":"Phase I","graph3":"Global Antibiotics Research and Development Partnership","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Antibiotics Research and Development Partnership \/ Parexel | KCAS Bio","highestDevelopmentStatusID":"6","companyTruncated":"Global Antibiotics Research and Development Partnership \/ Parexel | KCAS Bio"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Innoviva Specialty Therapeutics","sponsor":"Global Antibiotic Research & Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Zoliflodacin","moa":"DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva Specialty Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Innoviva Specialty Therapeutics \/ Global Antibiotic Research & Development","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva Specialty Therapeutics \/ Global Antibiotic Research & Development"}]

Find Clinical Drug Pipeline Developments & Deals for Zoliflodacin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Zoliflodacin,Azithromycin,Ceftriaxone

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : The Global Antibiotic Research and Development Partnership

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Details : Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          December 17, 2020

                          Lead Product(s) : Zoliflodacin,Azithromycin,Ceftriaxone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : The Global Antibiotic Research and Development Partnership

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Dr Reddy Company Banner

                          02

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : ETX-0914 (zoliflodacin) has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction.

                          Product Name : ETX-0914

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 10, 2025

                          Lead Product(s) : Zoliflodacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Global Antibiotic Research & Development

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Zoliflodacin, an antibiotic, is currently undergoing evaluation in late-stage clinical trials with patients for treating gonorrhea, in combination with ceftriaxone/azithromycin.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 24, 2024

                          Lead Product(s) : Zoliflodacin,Azithromycin,Ceftriaxone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Global Antibiotics Research and Development Partnership

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Global Antibiotics Research and Development Partnership

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Zoliflodacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 02, 2022

                          Lead Product(s) : Zoliflodacin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Parexel | KCAS Bio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          December 17, 2020

                          Lead Product(s) : Zoliflodacin,Azithromycin,Ceftriaxone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : The Global Antibiotic Research and Development Partnership

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Drugs for Neglected Diseases

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Drugs for Neglected Diseases

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Zoliflodacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gonorrhea.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          October 24, 2018

                          Lead Product(s) : Zoliflodacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Quotient Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : AZD0914 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 24, 2014

                          Lead Product(s) : Zoliflodacin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : AZD0914 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gonorrhea.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 28, 2013

                          Lead Product(s) : Zoliflodacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank